Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TG Therapeutics, Inc. - Common Stock (NQ: TGTX )

33.50 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 33.50
Bid (Size) 31.50 (2)
Ask (Size) 33.93 (1)
Prev. Close 33.50
Today's Range 33.50 - 33.50
52wk Range 12.84 - 36.84
Shares Outstanding 154,420,772
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TG Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
A Closer Look at TG Therapeutics's Options Market Dynamics
Via Benzinga

Performance

YTD
+96.60%
+96.60%
1 Month
-2.22%
-2.22%
3 Month
+43.59%
+43.59%
6 Month
+86.63%
+86.63%
1 Year
+96.48%
+96.48%

More News

Read More
NASDAQ:TGTX stands out as a growth opportunity that won't break the bank.
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
Via Investor's Business Daily
Topics Economy Government
Exposures Interest Rates Political
The Analyst Verdict: TG Therapeutics In The Eyes Of 5 Experts
Via Benzinga
Delving into NASDAQ:TGTX's Growth Prospects.
Via Chartmill
TG Therapeutics Crashes — Reversing A Breakout — On Its Mixed Third-Quarter Results
Via Investor's Business Daily
Why Yum China Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Napco Security Technologies Posts Downbeat Results, Joins Centrus Energy, Constellation Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
10 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why NASDAQ:TGTX qualifies as a high growth stock.
Via Chartmill
Unlocking the Growth Potential of NASDAQ:TGTX.
Via Chartmill
Evaluating TG Therapeutics: Insights From 4 Financial Analysts
Via Benzinga
AI Stocks Meta, Oracle Lead Five Names Near Buy Points
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Investors seeking growth at a reasonable cost should explore NASDAQ:TGTX.
Via Chartmill
NASDAQ:TGTX—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:TGTX is worth considering.
Via Chartmill
What's Going On With TG Therapeutics Stock Wednesday?
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Stock Market Hits Record Highs On Big Fed Rate Cut; Apple, Intel, FedEx In Focus: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
IBD 50's TG Therapeutics Surges On Five-Year Data For Multiple Sclerosis Drug
Via Investor's Business Daily
Despite its growth, NASDAQ:TGTX remains within the realm of affordability.
Via Chartmill
NASDAQ:TGTX—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via Chartmill
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.